These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16521811)

  • 1. [Prevention of the manifestation of diabetes in the elderly in the presymptomatic stage].
    Nagata M
    Nihon Ronen Igakkai Zasshi; 2006 Jan; 43(1):84-6. PubMed ID: 16521811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Primary prevention of diabetes mellitus type 2].
    Gallwitz B
    Internist (Berl); 2004 Jun; 45 Suppl 1():S15-22. PubMed ID: 15241504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
    Flórez H
    Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.
    Chiasson JL
    Endocr Pract; 2006; 12 Suppl 1():25-30. PubMed ID: 16627376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress in the prevention of type 2 diabetes].
    Schernthaner G
    Wien Klin Wochenschr; 2003 Nov; 115(21-22):745-57. PubMed ID: 14743578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
    Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
    Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Is it possible to prevent type 2 diabetes?].
    Laville M
    Ann Endocrinol (Paris); 2003 Jun; 64(3 Suppl):S37-44. PubMed ID: 12910058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and surgical intervention for the prevention of diabetes.
    Chiasson JL
    Nestle Nutr Workshop Ser Clin Perform Programme; 2006; 11():31-42. PubMed ID: 16820729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
    Hanefeld M; Schaper F
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):153-63. PubMed ID: 18248270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
    Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
    Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
    Hanefeld M; Chiasson JL; Koehler C; Henkel E; Schaper F; Temelkova-Kurktschiev T
    Stroke; 2004 May; 35(5):1073-8. PubMed ID: 15073402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Network Meta-analysis of the Therapeutic Effects of Hypoglycemic Drugs and Intensive Lifestyle Modification on Impaired Glucose Tolerance.
    Zhang Y; Fu Y; Mu YM; Huang Y; Xuan J
    Clin Ther; 2021 Sep; 43(9):1524-1556. PubMed ID: 34452739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance.
    Josse RG; McGuire AJ; Saal GB
    Int J Clin Pract; 2006 Jul; 60(7):847-55. PubMed ID: 16858756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of Type 2 diabetes: fact or fiction?
    Chiasson JL
    Expert Opin Pharmacother; 2007 Dec; 8(18):3147-58. PubMed ID: 18035959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug therapy in subjects with impaired glucose tolerance].
    Kawamori R; Yoshii H
    Nihon Rinsho; 1996 Oct; 54(10):2750-3. PubMed ID: 8914439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
    Ratner R; Goldberg R; Haffner S; Marcovina S; Orchard T; Fowler S; Temprosa M;
    Diabetes Care; 2005 Apr; 28(4):888-94. PubMed ID: 15793191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
    Delorme S; Chiasson JL
    Curr Opin Pharmacol; 2005 Apr; 5(2):184-9. PubMed ID: 15780829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of metformin for diabetes prevention.
    Slama G
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S104-11. PubMed ID: 14502107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.